Navigation Links
By Targeting Specific Germs, Hospital Hopes to Improve Pneumonia Treatment

By analyzing patient characteristics and the particular bacteria causing some patients to develop pneumonia during hospital stays// , Wake Forest University Baptist Medical Center has developed treatment guidelines to more effectively target the germs.

“We matched the best antibiotic combination to each patient’s characteristics and the particular bugs that we have in our hospital,” said James Beardsley, Pharm.D., lead author of the article in this month’s issue of the journal Chest. “We learned that some of the commonly recommended drugs wouldn’t have worked for many of our patients.”

The researchers estimate that antibiotic therapy under the new hospital-specific guidelines will target the correct bacteria in at least 90 percent of cases at risk of being resistant to treatment. If national guidelines were followed, treatment may have correctly targeted the germs in only 70 percent of cases.

Pneumonia is one of the most common hospital-acquired infections. The American Thoracic Society and the Infectious Diseases Society of America joined together to publish national guidelines for treating pneumonia that develops in health care settings, often as a result of patients being on respirators.

Once a patient develops pneumonia, it takes two or three days for laboratory tests to determine exactly what bacteria caused the illness. But treatment must begin right away, so physicians generally use an antibiotic known to be effective against the bacteria that most commonly cause pneumonia. Some patients, especially those who have been in the hospital for several days, are at risk of being infected with bacteria that are resistant to these drugs. This can make it challenging to select the correct antibiotics.

“The choice of which antibiotics to start is very important,” said Beardsley. “They need to cover the germs that are causing the pneumonia in that particular patient. If you’re not right from the start, people ar e at higher risk of dying.”

To improve the effectiveness of therapy, national guidelines recommend that hospitals base drug selection on the characteristics of the bacteria in their institutions. However, specific recommendations on how to accomplish this are not widely agreed on. Wake Forest Baptist’s report is believed to the first published description of a process using hospital data on infection-causing bacteria to develop institution-specific guidelines for treatment of pneumonia.

The Medical Center project was part of an overall effort to improve care of pneumonia acquired in the hospital. Team members reviewed six months of pneumonia cases from 2004 – a total of 115 cases – to learn which bacteria had caused the pneumonia. They found that at Baptist Hospital, it was patients who had been hospitalized at least 10 days who were most at risk of being infected with bacteria resistant to the most common antibiotics.

The group analyzed each episode of late-onset pneumonia to determine the adequacy of various drug combinations. The goal was to determine which drugs should be used and under what circumstances. They are currently looking at 2006 pathogens to see if the bacteria have changed – which could require an update of the internal guidelines.

In addition to making sure that patients get the most effective therapy, the project also helps the hospital be better stewards of antibiotics, Beardsley said.

“Improper use of antibiotics – whether it is under-dosing, over-use, or prescribing a drug that isn’t effective against the pathogen – hurts our ability to treat the next infected person because resistance can develop,” he said.

Sorce-Newswise
SRM
'"/>




Related medicine news :

1. Novel Technique For Targeting Small-Cell Lung Cancer
2. Targeting PARP1 Is Effective In Protecting HD Cells from Damage
3. Ad Campaign Targeting Republicans On Medicare Prescription Drug Program
4. Highly Potent TB Strain Plays Favorites Targeting Specific Ethnic Groups
5. New Asthma Medicine Targeting Vulnerable Inner-City Children Tested
6. Targeting a Single Gene Could Inhibit Bone Decay and Stimulate Bone Growth
7. Researchers Find Stem-cell Therapy Effective in Targeting Metastatic Cancer
8. Targeting the Adrenal Gland Could Be Key Against Heart Failure
9. Targeting SOCS-3 can Control Obesity
10. Sex Abstinence Programs Targeting School-goers may Not Produce Desired Effect , Study
11. Response to chemotherapy could be measured by Prostate-Specific Antigen Doubling Time
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/22/2017)... Peoria, IL (PRWEB) , ... May 22, 2017 ... ... HealthCare, is part of a larger group investing in InsightRX, an early stage ... a patient’s underlying biological and pharmacological characteristics. Greatpoint Ventures Innovation Fund ...
(Date:5/21/2017)... FL (PRWEB) , ... May 20, 2017 , ... Pot. ... it, find it, review it, and share its attributes like never before. More than ... directory to connect cannabis enthusiasts to stores, strains, products – and for the first ...
(Date:5/21/2017)... ... May 21, 2017 , ... ... longer than six months since you've seen a dentist, it's time for a ... and getting x-rays once per year. , Dental checkups are a relatively easy ...
(Date:5/19/2017)... ... May 19, 2017 , ... Springfield, Vermont-based law firm ... Titled " Ten Good Reasons To Hire An Experienced Personal Injury Attorney, " the ... an accident or injury. As the article says. if someone is injured due ...
(Date:5/19/2017)... ... 19, 2017 , ... As a groundbreaking surgeon on the frontline of prostate ... screenings. Early detection of the disease, he says, can make a world of difference. ... , stands alongside the Georgia Comprehensive Cancer Control’s (GC3) Prostate Cancer Task Force and ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)...  Bayer announced today that the latest research from ... the 53 rd Annual Meeting of the American ... in Chicago . ... liver and thyroid cancers, as well as lymphomas, and ... trial of copanlisib in patients with relapsed or refractory ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology: